Hinova Pharmaceuticals Receives FDA Proceed Authorization for its IND Application for HP568, an Orally Bioavailable Chimeric Degrader Targeting ER for ER+/HER2- Advanced Breast Cancer Treatment
Hinova Pharmaceuticals Inc. (688302.SH), a leading biopharmaceutical company dedicated to developing innovative cancer therapies, recently announced that the US Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for HP568，an investigational drug targeting Estrogen Receptor （ER）for the treatment of ER-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
About HP568
HP568 is an oral ER Proteolysis Targeting Chimera (PROTAC) protein degrader that degrades both wild-type ER and ERαmutants. In preclinical studies, HP568 has demonstrated promising antitumor activity in animal models, showcasing significant tumor reduction and a favorable safety profile both in vivo and in vitro.Breast cancer is one of the most common malignant tumors among women worldwide, accounting for 2.31 million new cases of breast cancer globally according to globocan cancer statistics 2022. Women with ER+/HER2- breast cancer ≤50 years old accounts for 65%, and 75% ≥ 50 years old.
HP568 is a potent PROTAC ER degrader, and it’s IND application has been approved by the US FDA and the National Medical Products Administration (NMPA) in China. The Chinese Phase Ⅰ/Ⅱ clinical trial application was approved by the NMPA in October 2024, and the FPI was completed in January 2025.
About Hinova Pharmaceuticals Inc.
Hinova is an international and clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for treating cancer and metabolic diseases. The company’s pipeline includes multiple investigational drugs targeting a variety of cancer types and metabolic disorders, all aimed at addressing significant unmet medical needs and improving patient outcomes.
Contact:
bd@hinovapharma.com
Note to Editors:
For more information about HP568 and ongoing studies, please visit Hinova’s website at http://buywowgold333.cn/en/
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D
